State Street
ALXO icon

State Street’s ALX Oncology ALXO Stock Holding History

State Street’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Buy
1,498,905
+1,323,077
+752% +$2.37M ﹤0.01% 3197
2026
Q1 		$353K Buy
175,828
+51,600
+42% +$98.3K ﹤0.01% 3740
2025
Q4 		$140K Buy
124,228
+12,300
+11% +$18.6K ﹤0.01% 3976
2025
Q3 		$205K Sell
111,928
-12,304
-10% -$10.7K ﹤0.01% 3907
2025
Q2 		$51.6K Sell
124,232
-594,621
-83% -$300K ﹤0.01% 4089
2025
Q1 		$448K Buy
718,853
+34,730
+5% +$41.7K ﹤0.01% 3620
2024
Q4 		$1.14M Buy
684,123
+12,747
+2% +$19.6K ﹤0.01% 3461
2024
Q3 		$1.22M Sell
671,376
-34,171
-5% -$127K ﹤0.01% 3450
2024
Q2 		$4.25M Buy
705,547
+151,680
+27% +$1.87M ﹤0.01% 2994
2024
Q1 		$6.18M Buy
553,867
+52,371
+10% +$736K ﹤0.01% 2836
2023
Q4 		$7.47M Buy
501,496
+112,137
+29% +$1.06M ﹤0.01% 2740
2023
Q3 		$1.87M Buy
389,359
+7,940
+2% +$43.1K ﹤0.01% 3364
2023
Q2 		$2.86M Sell
381,419
-12,525
-3% -$82K ﹤0.01% 3247
2023
Q1 		$1.78M Buy
393,944
+394
+0.1% +$2.98K ﹤0.01% 3378
2022
Q4 		$4.44M Buy
393,550
+8,987
+2% +$101K ﹤0.01% 3084
2022
Q3 		$3.68M Buy
384,563
+28,758
+8% +$335K ﹤0.01% 3207
2022
Q2 		$2.88M Sell
355,805
-1,777,939
-83% -$19.4M ﹤0.01% 3352
2022
Q1 		$36.1M Buy
2,133,744
+691,410
+48% +$11.8M ﹤0.01% 1962
2021
Q4 		$31M Buy
1,442,334
+580,779
+67% +$25.1M ﹤0.01% 2152
2021
Q3 		$63.6M Sell
861,555
-193,322
-18% -$12.9M ﹤0.01% 1624
2021
Q2 		$57.7M Buy
1,054,877
+127,438
+14% +$7.63M ﹤0.01% 1744
2021
Q1 		$68.4M Buy
927,439
+544,900
+142% +$42.9M ﹤0.01% 1515
2020
Q4 		$33M Buy
382,539
+269,016
+237% +$16.2M ﹤0.01% 1914
2020
Q3 		$4.28M Buy
+113,523
New +$4.46M ﹤0.01% 2855

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street's ALXO Position: Q2 2026 in Review

State Street increased its ALX Oncology (ALXO) stake by 752% in Q2 2026, buying an estimated $2.37M and bringing the position to 1,498,905 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

State Street first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $68.4M in Q1 2021. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • State Street held 1,498,905 shares of ALX Oncology worth $3.1M as of Q2 2026.
  • State Street bought 1,323,077 ALX Oncology shares in Q2 2026, an estimated $2.37M.
  • ALX Oncology made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3197 holding.
  • State Street first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • State Street's ALX Oncology position peaked at $68.4M in Q1 2021.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.